New study investigates stomach side effects of lung disease drug
NCT ID NCT06714812
First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 14 times
Summary
This study observes 100 Caucasian patients with idiopathic pulmonary fibrosis (IPF) who are taking nintedanib. The goal is to understand who is more likely to get diarrhea from the drug and how changing the dose can help manage this side effect. The study does not test a new treatment but aims to improve how current therapy is managed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
IRCCS Azienda Ospedaliera-Universitaria di Bologna
Bologna, Bologna, 40138, Italy
Conditions
Explore the condition pages connected to this study.